CD1/BCMA Dual Targeting: One too many targets in SLE Save
Dr. Alfred Kim reports on abstract 2465 (CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study), presented at the 2025 ACR Convergence meeting in Chicago.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.